Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 11/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | GABRP | O00591 | 2/20 | 0.74 |
| ▸ | GABRD | O14764 | 2/20 | 0.74 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.74 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.74 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.74 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.74 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.74 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.74 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.74 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.74 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19229447 | 1.00 | G6PD (1.00) | G6PDCYP3A4CYP1A2CYP2C9PMP22 | |
| SCHEMBL20781183 | 1.00 | G6PD (1.00) | G6PDCYP3A4CYP1A2CYP2C9PMP22 | |
| SCHEMBL642973 | 1.00 | G6PD (1.00) | G6PDCYP3A4CYP1A2CYP2C9PMP22 | |
| SCHEMBL21645690 | 1.00 | G6PD (1.00) | G6PDCYP3A4CYP1A2CYP2C9PMP22 | |
| SCHEMBL22593890 | 1.00 | G6PD (1.00) | G6PDCYP3A4CYP1A2CYP2C9PMP22 | |
| SCHEMBL17776488 | 1.00 | G6PD (1.00) | G6PDCYP3A4CYP1A2CYP2C9PMP22 | |
| SCHEMBL4557082 | 1.00 | G6PD (1.00) | G6PDCYP3A4CYP1A2CYP2C9PMP22 | |
| SCHEMBL18373713 | 1.00 | G6PD (1.00) | G6PDCYP3A4CYP1A2CYP2C9PMP22 | |
| SCHEMBL10381095 | 1.00 | G6PD (1.00) | G6PDCYP3A4CYP1A2CYP2C9PMP22 | |
| SCHEMBL597740 | 1.00 | G6PD (1.00) | G6PDCYP3A4CYP1A2CYP2C9PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0659072-B1 | PHARMACEUTICAL EMULSIONS CONTAINING BIOACTIVE STEROIDS | PHARMACIA AB (SE) | 2001-11-07 | — | — | EP | claimed |
| EP-0659072-A1 | PHARMACEUTICAL EMULSIONS CONTAINING BIOACTIVE STEROIDS | Pharmacia AB (SE) | 1995-06-28 | — | — | EP | claimed |
| WO-1995001162-A1 | PHARMACEUTICAL EMULSIONS CONTAINING BIOACTIVE STEROIDS | PHARMACIA AB (SE) | 1995-01-12 | — | — | WO | claimed |
| US-20240197754-A1 | ANTICONVULSANT ACTIVITY OF STEROIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-06-20 | — | — | US | disclosed |
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230116196-A1 | METHOD OF TREATING CNS DISORDERS WITH NEUROSTEROIDS AND GABAERGIC COMPOUNDS | SAGE THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20220395513-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220339176-A1 | Methods of Treatments to Prolong Gestation and Complications of Menstruation or Gestation | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-10-27 | — | — | US | disclosed |
| US-11279729-B2 | Heterodimer compositions and methods for the treatment of ocular disorders | RIPPLE THERAPEUTICS CORPORATION (CA) | 2022-03-22 | — | — | US | disclosed |
| US-20210347809-A1 | HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | RIPPLE THERAPEUTICS CORPORATION (CA) | 2021-11-11 | — | — | US | disclosed |
| US-5439900-A | Synergistic mixture of steroid and alcohol | BUKUSOGLU CUNEYT (US) | 1995-08-08 | — | — | US | disclosed |
| EP-0659072-A1 | PHARMACEUTICAL EMULSIONS CONTAINING BIOACTIVE STEROIDS | Pharmacia AB (SE) | 1995-06-28 | — | — | EP | disclosed |
| EP-0603312-A4 | NOVEL GABA A? RECEPTOR WITH STEROID BINDING SITES. | COCENSYS INC (US) | 1995-06-07 | — | — | EP | disclosed |
| WO-1995001162-A1 | PHARMACEUTICAL EMULSIONS CONTAINING BIOACTIVE STEROIDS | PHARMACIA AB (SE) | 1995-01-12 | — | — | WO | disclosed |
| EP-0603312-A1 | NOVEL GABA A? RECEPTOR WITH STEROID BINDING SITES | COCENSYS, INC. (US) | 1994-06-29 | — | — | EP | disclosed |
| EP-0554436-A4 | — | — | 1994-01-12 | — | — | EP | disclosed |
| EP-0554436-A1 | GABA RECEPTOR MODULATORS | COCENSYS, INC. (US) | 1993-08-11 | — | — | EP | disclosed |
| WO-1993005786-A1 | NOVEL GABAA RECEPTOR WITH STEROID BINDING SITES | COCENSYS, INC. (US) | 1993-04-01 | — | — | WO | disclosed |
| WO-1990005528-A2 | ANTI-THROMBOTIC STEROIDS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1990-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220339176-A1 | Methods of Treatments to Prolong Gestation and Complications of Menstruation or Gestation | PGF, GNRHR, PTGDR | G6PD 916/4885CYP3A4 1395/4885CYP1A2 765/4885 |
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | CYP21A2, CYP46A1, CYP17A1 | G6PD 1035/4885CYP3A4 175/4885CYP1A2 83/4885 |
| US-20230116196-A1 | METHOD OF TREATING CNS DISORDERS WITH NEUROSTEROIDS AND GABAERGIC COMPOUNDS | GABRB3, GABRB2, GABRB1 | G6PD 2605/4885CYP3A4 566/4885CYP1A2 178/4885 |
| US-20240197754-A1 | ANTICONVULSANT ACTIVITY OF STEROIDS | CYP21A2, HSD3B1, HSD17B2 | G6PD 3141/4885CYP3A4 541/4885CYP1A2 302/4885 |
| US-11279729-B2 | Heterodimer compositions and methods for the treatment of ocular disorders | CRYAB, UACA, CRYAA | G6PD 2109/4885CYP3A4 4704/4885CYP1A2 4465/4885 |
| US-20220395513-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | CYP21A2, CYP46A1, CYP17A1 | G6PD 1035/4885CYP3A4 175/4885CYP1A2 83/4885 |
| US-20210347809-A1 | HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | CRYAB, UACA, CRYAA | G6PD 2109/4885CYP3A4 4704/4885CYP1A2 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.